Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
apb-102 save search
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
IMNM | $14.64 -4.19% -4.37% 890K
|
Health Technology
|
| O: 0.0%
H: 6.46%
C: 5.79%
al102 pharmaceuticals
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
IMNM | $14.64 -4.19% -4.37% 890K
|
Health Technology
|
| O: -1.32%
H: 1.76%
C: -9.8%
ADXS | $0.572 12.48% 270
|
Health Technology
|
| O: 2.74%
H: 17.51%
C: 5.22%
al102 tumors pharmaceuticals study
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
IMNM | $14.64 -4.19% -4.37% 890K
|
Health Technology
|
| O: 2.01%
H: 34.44%
C: 34.2%
al102 treatment pharmaceuticals acquire
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
ADXS | $0.572 12.48% 270
|
Health Technology
|
| O: 6.74%
H: 0.0%
C: -10.53%
al102 drug tumors pharmaceuticals designation
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.572 12.48% 270
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 1.81%
H: 0.0%
C: 0.0%
al102 presentation pharmaceuticals al101
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published: 2023-07-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.19%
H: 1.07%
C: 0.65%
ADXS | $0.572 12.48% 270
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -7.09%
al102 fda tumors treatment pharmaceuticals meeting phase 2
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: 1.21%
H: 2.92%
C: 1.72%
apb-102 global als agreement therapy
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
Published: 2022-09-27 (Crawled : 12:20) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 10.95%
H: 8.15%
C: -20.22%
al102 fda pharmaceuticals designation granted fast track designation
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 1.85%
H: 1.0%
C: -3.43%
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 22.17%
H: 2.27%
C: -20.46%
abo-102 therapeutics therapy
Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors
Published: 2022-02-23 (Crawled : 22:00) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -4.52%
H: 7.35%
C: -4.98%
al102 phase 2 als phase 2/3 enroll
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
Published: 2021-11-17 (Crawled : 12:30) - globenewswire.com
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: -6.75%
H: 0.0%
C: 0.0%
presentation conference
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
Published: 2021-07-28 (Crawled : 12:00) - globenewswire.com
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 2.4%
H: 4.69%
C: 0.0%
fda gene therapy therapy aav9 gene therapies aβos syndros
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
Published: 2021-07-26 (Crawled : 12:00) - globenewswire.com
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 5.73%
H: 10.34%
C: -5.42%
treatment gene therapy therapy gene therapies aβos syndros train
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
Published: 2021-02-12 (Crawled : 17:00) - globenewswire.com
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: -1.13%
H: 12.88%
C: -10.9%
treatment phase 1 gene therapy positive therapy phase 3 phase 2 gene therapies aβos
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
Published: 2021-02-02 (Crawled : 13:00) - biospace.com/
ABEO | News | $3.395 -53.87% -116.79% 5.5M
|
Health Technology
|
| O: 3.09%
H: 2.4%
C: 1.5%
aβos
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.